Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 78

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 78
---
 of other awards is prohibited without stockholder approval. |

| • | No liberal share recycling. Liberal share recycling is not allowed. Shares withheld to pay the grant price or exercise price, or to satisfy a tax withholding obligation related to an award, will not again become available for awards under the Fifth Amended Plan. |

| • | Limitations on dividends and dividend equivalents. Dividends and dividend equivalents on shares and awards that have not vested and accrued dividends are not paid under the Fifth Amended Plan until the underlying shares vest. |

| • | Awards subject to claw back. There is a robust claw back provision under the Fifth Amended Plan. |

| • | Limit on non-employee director awards and other awards. The sum of any cash compensation and the value of awards (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes) granted to any of our non-employee directors as compensation for services during any calendar year may not exceed $500,000 (increased to $700,000 in the calendar year of his or her initial service). |

Why We Are Asking Our Stockholders to Approve the Fifth Amended Plan

| • | Equity incentives are key to retaining key talent to drive our business forward.The Board believes that equity awards are a key element underlying our ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully, through this time of transition for our Company, and implement our business plan to develop our pipeline of therapeutics. Equity awards align the interests of our key personnel with those of our stockholders and are a substantial contributing factor to our success and the future growth of our business. |

| • | Current shares available for awards are inadequate.We believe that the shares currently available for grant under the 2020 Plan will be insufficient to meet our anticipated retention and recruiting needs. As of June 18, 2025, there were 47,409 shares available for future grant under the 2020 Plan. |

Information regarding Equity Incentive Program, Dilution and Overhang The following table provides certain information regarding our equity incentive program:

|                                                                                                       |     |      As of 
   June 18, 
       2025 |
|:------------------------------------------------------------------------------------------------------|:----|-----------:|
| Total number of shares of Common Stock subject to outstanding stock options                           |     | $1,230,272 |
| Weighted-average exercise price of outstanding stock options                                          |     |      $3.79 |